Juanjuan Feng

Shanghai Key Laboratory Of Regulatory Biology And School Of Life Sciences
Shanghai, 200241, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Pan-KRAS inhibition: unlocking broad-spectrum targeted therapy for KRAS-mutant cancers.

Pan-KRAS inhibition: unlocking broad-spectrum targeted therapy for KRAS-mutant cancers.

Journal: Cancer biology & medicine

Published: February 10, 2026

A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers.

A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers.

Journal: Cancer cell

Published: October 05, 2024

Design, Synthesis, and Pharmacological Evaluation of Multisubstituted Pyrido[4,3-d]pyrimidine Analogues Bearing Deuterated Methylene Linkers as Potent KRASG12D Inhibitors.

Design, Synthesis, and Pharmacological Evaluation of Multisubstituted Pyrido[4,3-d]pyrimidine Analogues Bearing Deuterated Methylene Linkers as Potent KRASG12D Inhibitors.

Journal: Journal of medicinal chemistry

Published: November 03, 2023

Discovery of a Potent and Oral Available Complex I OXPHOS Inhibitor That Abrogates Tumor Growth and Circumvents MEKi Resistance.

Discovery of a Potent and Oral Available Complex I OXPHOS Inhibitor That Abrogates Tumor Growth and Circumvents MEKi Resistance.

Journal: Journal of medicinal chemistry

Published: May 02, 2023

Loss of PHF8 induces a viral mimicry response by activating endogenous retrotransposons.

Loss of PHF8 induces a viral mimicry response by activating endogenous retrotransposons.

Journal: Nature communications

Published: December 10, 2022

Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer.

Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer.

Journal: Oncogene

Published: December 09, 2022

Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer.

Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer.

Journal: Acta pharmaceutica Sinica. B

Published: May 15, 2022

BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer.

BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer.

Journal: The Journal of clinical investigation

Published: April 25, 2022

The oncoprotein BCL6 enables solid tumor cells to evade genotoxic stress.

The oncoprotein BCL6 enables solid tumor cells to evade genotoxic stress.

Journal: eLife

Published: April 09, 2021

Blocking STAT3 by pyrvinium pamoate causes metabolic lethality in KRAS-mutant lung cancer.

Blocking STAT3 by pyrvinium pamoate causes metabolic lethality in KRAS-mutant lung cancer.

Journal: Biochemical pharmacology

Published: January 10, 2020

BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors.

BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors.

Journal: The Journal of clinical investigation

Published: August 29, 2019

Triptolide suppresses pancreatic cancer cell proliferation by inhibiting hedgehog signaling pathway activity.

Triptolide suppresses pancreatic cancer cell proliferation by inhibiting hedgehog signaling pathway activity.

Journal: Science China. Life sciences

Published: November 23, 2018

Showing 1-12 of 12

Last Updated: 09/26/2026